Aclaris Therapeutics (NASDAQ:ACRS) is set for a significant down move on the heels of a failed Phase 2 clinical trial evaluating ATI-502 in patients with an autoimmune disorder characterized by hair loss called alopecia areata.
The study did not meet the primary or secondary endpoints due to high rates of disease resolution in the vehicle (placebo) arm.
Management will host a conference call at 5:00 pm ET to discuss the results.
Shares will resume trading at 4:30 pm ET.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.